Democratizing plasma proteomics: demonstrating a novel large-scale plasma proteomics targeted assay
Plasma is a rich source of protein biomarkers to reveal disease biology. However, identifying biomarkers in plasma proteomics has challenges due to the wide range of protein concentrations. The Orbitrap Astral mass spectrometer delivers a new set of performance standards for plasma proteomics, with deep proteome coverage, fast throughput, and accurate and precise quantitation. Use of a newly developed extracellular vesicle enrichment protocol and DIA enables new depths of plasma proteome coverage, quantifying more than 5000 proteins in 60 minutes.
While mass spectrometry is often envisioned as an unbiased discovery platform for protein quantitation, many use the technology for directed monitoring of relevant, predefined targets. Targeted methods based on parallel reaction monitoring (PRM) can be superior in terms of precision, accuracy, reproducibility, dynamic range, and specificity.
This webcast will describe the development of PRM assays and demonstrate the ability to measure >700 proteins using >1500 peptides in plasma on a novel hybrid nominal mass resolution tandem mass spectrometer, as well as demonstrate the statistical power in finding quantitative differences in a pilot Alzheimer’s disease cohort compared with DIA.
Learn:
- How to extend plasma proteome coverage using new enrichment strategies and new mass spectrometers for discovery
- How to efficiently and effectively transfer discovery-based plasma proteins for robust targeted quantitative analysis
- The analytical capabilities of a novel hybrid nominal mass resolution tandem mass spectrometer
This webcast has been produced by Thermo Fisher, who retains sole responsibility for content.
Presenter: Dr. Michael MacCoss (Professor of Genome Sciences, University of Washington)
Moderator: Moderator: Sarah Hiddleston (Science Journalist, Nature Research Custom Media)
